Affordable Access

Opportunities for newer agents in combination with oxaliplatin.

Authors
Type
Published Article
Journal
Seminars in Oncology
0093-7754
Publisher
Elsevier - WB Saunders
Publication Date
Volume
30
Issue
4 Suppl 15
Pages
62–67
Identifiers
PMID: 14523797
Source
Medline

Abstract

Oxaliplatin is a new third-generation platinum analogue with unique activity in colorectal cancer. This agent has changed the approach to chemotherapy for this disease. Novel biologic or molecular targeting agents are now under study in phase I to III clinical trials. Many of these agents are quite promising in colorectal cancer therapy. Most advanced among these include anti-vascular endothelial growth factor antibodies, antibodies directed against the epidermal growth factor receptor (HER-1), small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor, and the proteasome inhibitor PS-341 (bortezomib). The rationale for combinations with oxaliplatin and early clinical trial results are discussed.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments